Feasibility and Safety of IL-15-Activated CD56+ Cell Therapy in High-Risk Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation: Phase I Clinical Trial.

PubMed 2026

View at publisher
Authors: Shiva Eskandarian, Amirhossein Izadpanah, Mozhdeh Mohammadian, Mehdi Bakhtiyaridovvmbaygi, Mehrshad Seresht-Ahmadi, Sahar Parkhideh, Elham Roshandel, Ahmad Gharehbaghian, Abbas Hajifathali
DOI: 10.22074/cellj.2025.2057631.1827
Cited by: 2

Abstract

Objective: cells and assessed the safety of their infusion in AML patients following allo-HSCT. Materials and Methods: cells/kg of patient bodyweight were infused to the three patients on days +7, +14, and +21 post-allo-HSCT. Patients were observed during and up to 4 hours after the infusion for immediate adverse events and were monitored for 21 days to detect delayed events. Results: cells. This method was safe and no intervention-related complications were observed. Conclusion: cells with IL-15, further studies with larger sample sizes are needed to confirm and validate the current hypothesi (registration number: IRCT20230801058996N2).

Fields of Study & Subjects

Immune Cell Function and Interaction CAR-T cell therapy research Acute Myeloid Leukemia Research

Publication details

Journal / source
PubMed
Volume
27
Issue
1
Pages
1–9
Publication date
14 February 2026
Language
EN